Observations placeholder
Viibryd , Vilazodone
Identifier
017334
Type of Spiritual Experience
Number of hallucinations: 215
Background
A description of the experience
Vilazodone (United States trade name Viibryd is a serotonergic antidepressant developed by Clinical Data for the treatment of major depressive disorder. Vilazodone was approved by the FDA for use in the United States to treat major depressive disorder in 2011.
Vilazodone acts as a serotonin reuptake inhibitor (IC50 = 2.1 nM; Ki = 0.1 nM) and 5-HT1A receptor partial agonist (IC50 = 0.2 nM; IA = ~60–70%)
On Aug, 7, 2015: 1,584 people reported to have side effects when taking Viibryd. Among them, 1 people (0.06%) has Death.
Time on Viibryd when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Dec, 21, 2016 4,514 people reported to have side effects when taking Viibryd. Among them, 160 people (3.54%) have Hallucination
On Dec, 24, 2016 4,514 people reported to have side effects when taking Viibryd. Among them, 37 people (0.82%) have Hallucination, Auditory
On Dec, 26, 2016 478 people reported to have side effects when taking Vilazodone Hydrochloride. Among them, 18 people (3.77%) have Hallucination